Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Selecta Biosciences, Inc. (SELB)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
1.2700+0.0300 (+2.42%)
At close: 04:00PM EST
1.2500 -0.02 (-1.57%)
After hours: 07:47PM EST
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Commodity Channel Index

Commodity Channel Index

Previous Close1.2400
Open1.2500
Bid1.2500 x 2900
Ask1.3200 x 1800
Day's Range1.2500 - 1.3099
52 Week Range0.6470 - 3.6400
Volume579,511
Avg. Volume773,112
Market Cap194.349M
Beta (5Y Monthly)0.91
PE Ratio (TTM)4.88
EPS (TTM)0.2600
Earnings DateNov 03, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est6.86
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Near Fair Value
4% Est. Return

Subscribe to Yahoo Finance Plus to view Fair Value for SELB

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Selecta Biosciences, Inc.
    Analyst Report: Pfizer Inc.Pfizer is one of the world's largest pharmaceutical firms, with annual sales close to $50 billion. Pfizer also spends a leading amount on research and development, close to $8 billion annually. While Pfizer historically sold many types of healthcare products and chemicals, now, prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13, cancer drug Ibrance, cardiovascular treatment Eliquis, and immunology drug Xeljanz. Pfizer sells these products globally, with international sales representing close to 50% of its total sales. Within international sales, emerging markets are a major contributor.
    Rating
    Fair Value
    Economic Moat
    2 years agoMorningstar
View more
  • GlobeNewswire

    Selecta Biosciences Announces Appointment of Blaine Davis as Chief Financial Officer

    WATERTOWN, Mass., Nov. 28, 2022 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therapies for autoimmune diseases, unlock the potential of gene therapies and amplify the efficacy of biologic therapies, announced the appointment of Blaine Davis as Chief Financial Officer, effective today, November 28, 2022. “Blaine is a highly accomplished biopharmaceutical executive with proven finan

  • Simply Wall St.

    Selecta Biosciences Third Quarter 2022 Earnings: Misses Expectations

    Selecta Biosciences ( NASDAQ:SELB ) Third Quarter 2022 Results Key Financial Results Revenue: US$20.7m (down 15% from...

  • GlobeNewswire

    Selecta Biosciences to Participate at the Guggenheim Healthcare Talks | 4th Annual Immunology & Neurology Day

    WATERTOWN, Mass., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company pioneering precision immune tolerance with its clinically validated ImmTOR® platform to develop tolerogenic therapies for autoimmune diseases, unlock the potential of gene therapies and amplify the efficacy of biologic therapies, today announced that Company’s Management will participate in a presentation and one-on-one investor meetings at the Guggenheim Healthcare Talks | 4th A

Advertisement
Advertisement